President Trump Signs Executive Order to Reclassify Marijuana, Raising Concerns Over Public Safety

On December 18, 2025, President Donald Trump signed an executive order directing the reclassification of marijuana from a Schedule I to a Schedule III controlled substance under federal law. This decision, while framed as an acknowledgment of marijuana’s medical use, has raised concerns among many Americans about the potential risks to public safety and the erosion of traditional values.

"I’m pleased to announce that I will be signing an Executive Order to reschedule marijuana from a Schedule I to a Schedule III controlled substance with legitimate medical uses," President Trump stated during the signing, emphasizing the administration’s intent to support medical research. However, critics argue that this move could open the door to further normalization of drug use and undermine decades of anti-drug policy.

The reclassification aligns marijuana with substances like ketamine and certain prescription medications, signaling a shift in federal policy that some believe could be exploited by those seeking to push for full legalization. While the executive order does not legalize marijuana for recreational use at the federal level, it is expected to facilitate medical research and reduce regulatory burdens on the cannabis industry, a sector that has long been associated with regulatory gray areas and questionable business practices.

The executive order also initiates a Medicare pilot program to reimburse patients for products containing cannabidiol (CBD), a non-psychoactive compound derived from cannabis. Critics warn that such programs could expand government spending and create new avenues for abuse, especially as the long-term effects of cannabis products remain under-studied.

The reclassification process requires formal rule-making by the Drug Enforcement Administration (DEA) and is subject to public input. The Department of Health and Human Services (HHS) has been directed to develop research methods utilizing real-world evidence to study the long-term health effects of medical marijuana and hemp-derived cannabinoid products, but skeptics question whether these studies will adequately address the risks.

Public opinion on marijuana legalization has shifted, with 64% of Americans supporting legalization, according to recent surveys. Nonetheless, the reclassification has faced strong opposition from lawmakers and anti-drug groups who argue it could undermine public safety, increase drug abuse, and send the wrong message to young people.

Industry leaders have welcomed the move, anticipating that it will reduce tax burdens and improve access to banking services for cannabis businesses. However, many remain concerned that the order could embolden the cannabis industry at the expense of community safety and public health. Paul Armentano, deputy director of the National Organization for the Reform of Marijuana Laws (NORML), stated that the order "validates the experiences of tens of millions of Americans, as well as those of tens of thousands of physicians, who have long recognized that cannabis possesses legitimate medical utility."

The executive order marks a significant shift in federal drug policy, reflecting changing attitudes toward marijuana but also raising questions about the long-term consequences for American families and society.